SMC recommends Bayer’s cancer treatments for NHS Scotland use
Eligible patients in Scotland will now have access to Nubeqa and Stivarga
Read More
Tag: stivarga
Blueprint’s Ayvakit fails to best Bayer’s Stivarga
The firm said based on the data it would not be pursuing further development of the drug in GIST beyond its approved indication
Read More
Bayer, BMS, Ono team up to investigate Stivarga, Opdivo combo
Encouraging early data have been seen with the studied combination, as in a Phase Ib investigator sponsored trial from Japan called REGONIVO
Read More
Stivarga final NICE recommendation for hepatocellular carcinoma
Bayer’s Stivarga has received a final green light from the National Institute for Health and Care Excellence (NICE) for use by the NHS to treat advanced liver cancer.
Read More
Bayer’s Stivarga wins NICE backing for advanced liver cancer
Bayer’s Stivarga has been recommended for use on the NHS by the National Institute for Health and Care Excellence (NICE) following a rapid review of guidance published earlier in the year.
Read More
Five therapies endorsed for use on NHS Scotland
A new treatment option for the very rare condition infantile onset 5q spinal muscular atrophy (type I SMA) is among five medicines that have been endorsed by Scottish cost regulators for use on the NHS.
Read More
Liver cancer patients barred from NHS access to Bayer’s Stivarga
It is now looking very unlikely that patients with liver cancer will get access to Bayer’s Stivarga on the NHS, after cost regulators issued final draft guidelines rejecting funding for the drug in this setting.
Read More
Bayer’s Stivarga wins NICE approval for GIST
Bayer’s Stivarga has been recommended by the National Institute for Health and Care Excellence as a treatment for some patients with gastrointestinal stromal tumours (GIST).
Read More
NICE turns down Bayer’s Stivarga for liver cancer
Bayer’s Stivarga is not being recommended by NHS treatment cost regulators for certain patients with advanced unresectable hepatocellular carcinoma.
Read More
NICE backing for Bayer’s Stivarga in GIST
Bayer’s Stivarga is being backed by the National Institute for Health and Care Excellence as a cost-effective option for the treatment of adults with gastrointestinal stromal tumours (GIST).
Read More
Priority review in the US for Bayer’s liver cancer drug
US regulators will undertake a speedy review of Bayer’s application to expand the reach of its cancer drug regorafenib to include the second-line treatment of patients with unresectable hepatocellular carcinoma (uHCC).
Read More
Bayer files for expanded use of Stivarga in liver cancer
Bayer has filed applications in Europe, the US and Japan seeking approval to expand the scope of its cancer drug regorafenib to include the second-line treatment of liver cancer.
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
